Fortrea (FTRE) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 9, 2026, with shareholders of record as of April 15, 2026, eligible to vote on key proposals.

• The company is a global provider of clinical development solutions, operating in about 100 countries with 14,300 employees.

• Forward-looking statements address business, financial, operational, compensation, and ESG matters, with risks disclosed in the annual report.

Voting matters and shareholder proposals

• Shareholders will vote on electing three Class III directors, ratifying Deloitte & Touche LLP as auditor for 2026, and an advisory say-on-pay vote for executive compensation.

• Board recommends voting FOR all proposals.

• Shareholders may submit proposals for the 2027 meeting by December 28, 2026, and director nominations per bylaw requirements.

Board of directors and corporate governance

• Board consists of eight members, transitioning from a classified structure to annual elections by 2028.

• All directors except the CEO are independent per Nasdaq standards.

• Board committees include Audit, Management Development and Compensation, and Nominating, Corporate Governance and Compliance, all composed of independent directors.

• Board leadership separates Chairman and CEO roles; periodic self-evaluations are conducted.

• Stockholder engagement includes regular outreach, earnings calls, and investor conferences.